근시 및 노안 치료 시장 - 예측(2026-2031년)

Myopia And Presbyopia Treatment Market is forecasted to rise at a 8.47% CAGR, reaching USD 46.307 billion in 2031 from USD 28.434 billion in 2025.

The myopia and presbyopia treatment market encompasses a dynamic and expanding spectrum of corrective and therapeutic solutions for two of the most prevalent refractive errors globally. While distinct in their etiology-myopia primarily driven by axial elongation and presbyopia by age-related loss of lens accommodation-their combined market is propelled by powerful, interconnected demographic and lifestyle trends. The growing global prevalence of both conditions, fueled by an aging population and modern behavioral shifts, alongside continuous technological innovation, is creating sustained demand across surgical, pharmacological, and optical correction segments.

A fundamental and potent driver for the myopia treatment segment is the rising global prevalence of myopia, particularly its early onset and progression in younger populations. This trend is strongly correlated with lifestyle factors associated with urbanization, including increased engagement in prolonged near-work activities (extensive digital device usage), reduced time spent outdoors, and educational pressures. The shift towards these environmental and behavioral patterns is creating a larger and younger patient pool requiring intervention, not only for refractive correction but increasingly for treatments aimed at slowing myopic progression itself to mitigate long-term ocular health risks.

Concurrently, the presbyopia treatment segment is being directly and irreversibly driven by global demographic aging. As a natural, age-related condition affecting near vision, the increasing proportion of the population over the age of 40 represents a vast and expanding addressable market. This demographic is typically more health-aware and possesses greater discretionary spending power, seeking solutions that extend beyond basic reading glasses to more advanced optical corrections, surgical options, and emerging pharmacological therapies that restore functional near vision and support an active lifestyle.

Technological advancement serves as a critical catalyst across the entire market. In surgical correction, innovations continue to refine outcomes. For myopia, wavefront-guided and topography-guided laser procedures (LASIK, PRK, SMILE) enhance precision and customization. For presbyopia, advancements include extended depth-of-focus and multifocal intraocular lenses (IOLs), corneal inlays, and laser-based presbyopia correction techniques. Beyond surgery, significant research and development is focused on pharmacological treatments for presbyopia, investigating novel topical agents designed to temporarily improve near vision by modulating pupil size or depth of focus, representing a potential paradigm shift towards non-invasive management.

Parallel to technological progress is the role of increasing public and professional awareness. Educational campaigns by healthcare organizations, professional societies, and industry participants are elevating the understanding of both conditions as treatable health issues rather than inevitable inconveniences. This heightened awareness is encouraging earlier diagnosis, discussion of a broader range of treatment options with eye care professionals, and greater patient demand for interventions that align with specific lifestyle needs, thereby driving market growth and sophistication.

Geographically, North America remains a dominant and mature market. This position is reinforced by a high prevalence of refractive errors, a well-established infrastructure of advanced ophthalmic care centers, high patient awareness, and favorable reimbursement frameworks for many surgical procedures. The region's concentration of leading medical device and pharmaceutical companies also fosters a rapid adoption cycle for innovative technologies and serves as a primary hub for clinical research and development.

Despite strong growth drivers, the market faces several restraints that impact accessibility and adoption. A significant barrier is the high out-of-pocket cost associated with many advanced treatments, particularly elective refractive surgeries and premium IOLs, which may not be fully covered by insurance plans. This cost sensitivity can limit uptake, especially in price-conscious segments. Furthermore, concerns regarding the safety, efficacy, and potential side effects of surgical procedures or novel pharmacological agents can create patient hesitancy, necessitating extensive counseling and trust-building by practitioners. Access to specialized eye care services and advanced diagnostic technology also remains uneven, particularly in rural and underserved regions globally, creating disparities in treatment availability.

The competitive landscape is characterized by a mix of large, diversified ophthalmic device companies, specialized pharmaceutical firms, and optical product manufacturers. Key players compete on the basis of technological leadership in laser platforms and IOL design, robust clinical data supporting safety and efficacy, and comprehensive service and training support for eye care professionals. Strategic focus areas include developing combination therapies for myopia control, next-generation presbyopia-correcting IOLs with reduced dysphotopsias, and bringing the first wave of FDA-approved pharmacological presbyopia treatments to market.

In conclusion, the myopia and presbyopia treatment market is evolving from a focus solely on refractive correction towards a more holistic model encompassing disease modification, functional restoration, and personalized management. Its growth is structurally supported by inescapable demographic and lifestyle trends that are expanding the global patient base. Future market development will be shaped by the successful commercialization of novel pharmacological agents, continued refinement of surgical outcomes and patient experience, and efforts to improve the cost-effectiveness and accessibility of advanced treatments. The convergence of these factors positions the market for ongoing innovation and expansion as it addresses the visual needs of a growing and aging global population.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Myopia and Presbyopia Treatment Market Segmentation

• By Disease Type
• Myopia
• Presbyopia
• By Treatment Type
• Prescription Lenses
• Contact Lenses
• Surgery
• Medication
• By End-User
• Hospitals
• Eyecare Centers & Clinics
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY DISEASE TYPE

• 5.1. Introduction
• 5.2. Myopia
• 5.3. Presbyopia

6. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY TREATMENT TYPE

• 6.1. Introduction
• 6.2. Prescription Lenses
• 6.3. Contact Lenses
• 6.4. Surgery
• 6.5. Medication

7. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Eyecare Centers & Clinics
• 7.4. Others

8. MYOPIA AND PRESBYOPIA TREATMENT MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End-User
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Disease Type
  • 8.3.2. By Treatment Type
  • 8.3.3. By End-User
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Disease Type
  • 8.4.2. By Treatment Type
  • 8.4.3. By End-User
  • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Italy
    • 8.4.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Disease Type
  • 8.5.2. By Treatment Type
  • 8.5.3. By End-User
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Disease Type
  • 8.6.2. By Treatment Type
  • 8.6.3. By End-User
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. India
    • 8.6.4.3. Japan
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Thailand
    • 8.6.4.7. Taiwan
    • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Ziemer Ophthalmic Systems AG
• 10.2. ALCON Inc.
• 10.3. Bausch Health Companies Inc.
• 10.4. Essilor Ltd
• 10.5. Johnson & Johnson
• 10.6. NIDEK CO. LTD
• 10.7. Topcon Corporation
• 10.8. Carl Zeiss
• 10.9. AbbVie
• 10.10. Cooper Companies Inc

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations